New Delhi: The All India Institute of Medical Sciences (AIIMS) here will begin the phase 2/3 trial of the Hyderabad-based Covid-19 vaccine manufacturer, Bharat Biotech’s Nasal Vaccine immediately, the sources informed on Wednesday.
In the midst of ongoing research in many countries to develop nasal sprays to help prevent Covid-19, Intrasal Vaccine Bharat Biotech received regulatory approval for the second phase trial in August.
The source told Ani that the Premier Hospital and the State Research Center will begin trials within a few weeks and the application has been included to look for the required permission of the AIIMS Ethics Committee.
The investigator of the Clinical Court Vaccine Vaccine Bharat Biotech will be Dr.
Sanjay Rai.
After obtaining a committee ethics nod, the second phase of the trial will be conducted on volunteers who will be given two vaccine doses with a distance of four weeks in between.
The Intrasal Adenoviral Vaccine BBV154 is the first of the Covid-19 vaccine type to undergo human trials in India.
According to the Ministry of Science and Technology, Phase 1 trial in healthy volunteers the age group ranging from 18-60 years well tolerated.
The trial for Phase 3 trials will begin after the completion of the phase-2 clinical trial.
AIIMS Delhi has also conducted covaxin clinical trials in the age group 2 to 18 years.